Struthers Richard Scott sold (to issuer) $83.1M of CRNX (indirect holdings)
Struthers Richard Scott (President & CEO) sold (to issuer) 978,205 indirectly-held shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($83.15M total) across 10 trades on 2026-09-01.
How this was made
The 30-second read
Why it matters
Large insider sell can trigger short‑term price pressure but may not affect long‑term fundamentals.
Market read
Primary disclosure of a significant insider sale; relevant for traders monitoring CRNX.
What to watch
Potential tax planning or personal financial needs may drive the transaction.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
CEO Richard Scott sold 978,205 shares for $85 each, totaling $83.1M, reducing his stake to zero.
Potential short-term price decline as market digests the $83M sale.
The sale represents a significant cash outflow by the CEO, often interpreted as a negative signal for investors.
Market effects
May raise concerns for biotech sector investors about insider confidence.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance beyond CRNX shareholders.
Counterpoint
The sale could be a routine liquidity event unrelated to company outlook.
Key entities
- CompanyCrinetics Pharmaceuticals, Inc.
Biopharmaceutical company listed on NASDAQ (CRNX).
- ExecutiveRichard Scott
President & CEO of Crinetics, reporting the insider sale.
